Mixtard 30 Flexpen 100 IU/ml Novo Nordisk treatment for diabetes (5 trees x 3ml)
Dosage form Box of 5 trees x 3ml
Specifications Soluble insulin, insulin isophan
Ingredient
| Composition information | Content |
| Dissolved insulin | 30% |
| Insulin isophan | 70% |
Uses
Indications
pen injection pens 30 flexpen are indicated in the following cases:
Mixtard 30 is dual -acting insulin.
Starting to work within ½ hours, maximum efficiency tronq round 2 - 8 hours and 24 -hour effect time.
Pharmacokinetics
absorption
Data on absorption is because the product is a mixture of insulin with fast and extended absorption. The highest concentration in the plasma of insulin works quickly achieved within 1.5 - 2.5 hours after subcutaneous injection.
Distribution
Not strongly attached to plasma proteins, except for anti -insulin antibodies during the circulation (if any) have been observed.
Metabolism
human insulin is reported by insulin protease or enzyme with insulin varies and possibly due to Isulfide protein isomerase. Some cutting positions (hydrolysis) on the proposed human insulin molecule; After cutting, no metabolites are formed.
Elimination
The last half -life is determined by the absorption rate from the subcutaneous tissue. Therefore, the final half -life (T1/2) is a measure of absorption rather than the excretion per second of insulin from plasma (blood insulin with t1/2 minutes). The tests show that T1/2 is about 5 - 10 hours.
Before taking Mixtard 30 Flexpen 100 IU/ml Novo Nordisk treatment for diabetes (5 trees x 3ml)
How to use
mixtard 30 flexpen Use subcutaneously. Insulin mixture is never intravenously.
Please read the following user manual before using the mixpen mixpen.
Your flexpen is a insulin injection pen dose by unique rotation. You can choose a private dose of 1 to 60 units, with hiccups per unit. Flexpen is designed for use with Kirn Novofine or Novotvvist needle used once with a length of 8 mm. To be cautious, always carry a prophylactic insulin in case Flexpen is lost or damaged.
Dosage
Mixtard is a dual -acting insulin. This is a two -phase formula including fast -acting insulin and prolonged acting insulin. Pre -mixed insulin products are usually used once or twice a day when it is necessary to have a quick starting effect with a longer -lasting effect.
Dosage
Dosage depends on each individual and is determined according to the needs of the patient. The insulin needs of each individual usually from 0.3 to 1.0 IU/kg/day. Daily insulin demand may be higher in insulin resistance patients (for example, in puberty or obesity) and lower in patients producing surplus endogenous insulin. There should be main meals or snacks containing carbohydrates within 30 minutes after each injection.
Dose adjustment
The accompanying disease, especially infection and fever, often increases the patient's insulin needs. Diseases that accompany the kidneys, liver or diseases affect the adrenal glands, pituitary or thyroid gland may require replacement of insulin doses. It may also be necessary to adjust the dose if the patient changes physical activity or normal diet. The adjustment of the dose may also be necessary when transferring patients from an insulin preparation to another type.
Note: The above dose is for reference only. Dosage of diabetes in mixtard depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?
When the patient wakes up, the food contains carbohydrates to prevent recurrence.
What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.
Side Effects
When using mixtard 30 flexpen , you may experience unwanted effects (ADR).
Very common, ADR> 1/10
Metabolic and nutrient disorders: Hypoglycemia.
Uncommon, 1/1000 immune system disorders: rash urticaria , rash. Nervous system disorders: peripheral neuropathy (neuropathy). eye disorders: diabetes retinopathy. Skin and tissue disorders: Fatty disorders. Systemic disorders and injection status: reaction at the injection site, edema. Very rare, ADR immune system disorders: Anaphylaxis. Eye disorders: refractive disorders. Instructions on how to handle ADR When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.
Warnings
Before using the drug you need to read the instructions carefully and refer to the information below.
Contraindicated
mixtard 30 flexpen contraindicated in the following cases:
Hypersensitivity to active ingredients or any excipients of the drug.
Caution when using
The treatment is not enough or not continuous, especially in TIP 1 diabetes, which can lead to hyperglycemia.
Normally, the first symptoms of hyperglycemia appear slowly, lasting for several hours or days. These symptoms include thirst, urination, nausea, vomiting, drowsiness, red skin, dry mouth, loss of appetite as well as acetone smell.
In tip 1 diabetes, cases of untreated hyperglycemia will lead to diabetic acid ceton infection, which is likely to be fatal.
Hypoglycemia may occur if insulin dose is too high compared to insulin needs.
Skipping a meal or exercise, no plan that can lead to hypoglycemia. Patients with blood glucose control are improved, for example, due to enhanced insulin therapy, there may be changes in the common warning symptoms of hypoglycemia and must be notified by the doctor. Common warning symptoms can be lost in patients with diabetes for a long time.
When transferring patients to use another type of insulin or other insulin brand, it must be performed under tight medical supervision. Changes in concentration, brand (manufacturer), type, origin (human insulin, insulin analogue) and/or production method can lead to the need for dose changes.
Patients who are transferred to insulin mixtard injecting pen from another type of insulin may have to increase some daily injections or change the dose of the insulin they have used earlier. If the adjustment is necessary when transferring the patient to using a mixtard, it can be done at the first dose or in the first few weeks or the first few months. Like any other insulin therapy, the reactions may occur in the injection site, including pain, redness, urticaria, inflammation, bruising, swelling and itching.
Continuous changes in the injection site in a certain injection area can help reduce or prevent these reactions. The above reactions often pass in a few days to a few weeks. In rare cases, the response at the injection site may require stopping using mixtard. Before traveling to the place of time zone, patients should consult a doctor, because this means that the patient must inject insulin and use meals at other times. Do not use insulin mixture in insulin transmission.
Combining thiazolidinedione and insulin drugs
Cases of congestive heart failure when using thiazolidinedione combined with insulin have been reported, especially in patients with risk factors for congestive heart failure. This should be remembered if considering the combination of thiazolidinedione with insulin drugs. If used in combination, patients must monitor the signs and symptoms of congestion, weight gain and edema. Must stop using thiazolidinedione if any heart worsening symptoms occur.
The ability to drive and operate machinery
The patient's concentration and reaction ability may be impaired as a result of hypoglycemia. This can be dangerous in situations where the possibilities are of special importance (such as driving or operating machinery).
Patients must be notified to take measures to prevent hypoglycemia when driving, which is especially important in patients who are difficult to identify or not recognize signs of hypoglycemia or in people who often have hypoglycemia. It is necessary to consider the suitability of driving in these cases.
Pregnancy
There is no restriction on the treatment of diabetes in pregnant women because insulin does not pass the placenta. Both hypoglycemia and hyperglycemia may occur in the case of incomplete treatment for diabetes control, which may increase the risk of birth defects and pregnancy in the uterus.
Recommendation to enhance blood glucose control and monitor pregnant women with diabetes during pregnancy and when intended to become pregnant.
The demand for insulin usually decreases in the first 3 months of pregnancy and will increase gradually in the middle and the last 3 months of pregnancy.
After birth, insulin demand quickly returns to the level as before pregnancy.
The period of breastfeeding
There is no restriction on the use of drugs during breastfeeding. The insulin treatment for nursing mothers is not at risk for babies. However, the dose, diet or both.
Interactive drug
Some drugs are known to interact with the metabolism of glucose.
The following substances can reduce the patient's insulin needs
Oral diabetes treatment, Monoamine oxidase inhibitors (MAOI), unsatisfactory beta blockers, angiotensin (ACE), Salicylate, Salicylate and Sulphonamide.
The following substances can increase the patient's insulin demand
Oral contraceptives, thiazide, glucocorticoid, thyroid hormone, sympathetic strength, growth hormone and danazol.
Beta blockers can cover signs of hypoglycemia and slow down healing after hypoglycemia.
octreotide /Lankeotide may increase or decrease the demand of insulin.
Wine can increase or decrease the demand of insuslin.
Storage
Store in the refrigerator (2 - 8oC). To far from the cooling unit. Avoid freezing.
Close the lid of the pen to avoid light. To avoid excessive heat or light.
After the first opening or backup: not in the refrigerator.
When using: The expiry date of 6 weeks when stored below 30 ° C.
Other drugs
- ATOZET 10 MG/20 MG FILM-COATED TABLETS
- DAKTACORT CREAM
- LIPANTHYL MICRO 200MG CAPSULES
- MAXEPA CAPSULES
- PYRALVEX SOLUTION OROMUCOSAL SOLUTION
- ZINNAT SUSPENSION 250MG/5ML
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions